deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT02268851

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies

Sponsor: Blood Cancer Research Partnership

Conditions Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Mantle Cell Lymphoma
Interventions Ibrutinib TGR-1202
Updated 20 times since 2017 Last updated: Sep 11, 2024 Started: Nov 30, 2014 Primary completion: May 31, 2018 Completion: Oct 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02268851, this PHASE1 trial focuses on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Mantle Cell Lymphoma and remains completed. Sponsored by Blood Cancer Research Partnership, it has been updated 20 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jan 2018 · 11 months · monthly snapshot~Jan 2018 – ~Apr 2018 · 3 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Mar 2019 · 8 months · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jul 2020 · 15 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Sep 2022 · 10 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~Oct 2023 · 6 months · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Jun 2024 · 4 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – present · 20 months · monthly snapshot

Change History

20 versions recorded

  1. Dec 2024 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Dec 2024 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. Feb 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 15 earlier versions

  1. Dec 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Oct 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE1

  3. Apr 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1

  4. Sep 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1

  5. Nov 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  6. Jan 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE1

  7. Jul 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  8. Apr 2019 — Jul 2020 [monthly]

    Active Not Recruiting PHASE1

  9. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1

  10. Jul 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE1

  11. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE1

  12. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  13. Jan 2018 — Apr 2018 [monthly]

    Recruiting PHASE1

  14. Feb 2017 — Jan 2018 [monthly]

    Recruiting PHASE1

  15. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Nov 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Blood Cancer Research Partnership
  • Dana-Farber Cancer Institute
  • TG Therapeutics, Inc.
  • The Leukemia and Lymphoma Society
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations